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Cardiac resynchronisation therapy (CRT) emerged more than
a decade ago as a useful form of device therapy for heart
failure associated with abnormal ventricular conduction indi-
cated by a wide QRS complex [1, 2]. According to the
Guidelines of the European Society of Cardiology (ESC)
entitled Cardiac Pacing and Cardiac Resynchronization
Therapy (ESC Clinical Practice Guidelines, 2013), CRT has
currently a Class I indication in patients with 1) chronic heart
failure (NYHA Class II-IV despite optimal medical treat-
ment), 2) a left bundle branch block (LBBB) on the ECG with
a QRS width >120 ms (preferably >150 ms), and 3) a left
ventricular ejection fraction<35% [3]. Themagnitude of CRT
benefit increases in females, in patients with non-ischaemic
cardiomyopathy, and in patients with a wide QRS complex:
the longer the QRS duration the more favourable the response.
CRT consists of biventricular pacing with or without an
internal cardioverter defibrillator (ICD): in combination with
an ICD, CRT is called CRT-D (efibrillator); without an ICD,
the treatment is called CRT-P (acing). According to Daubert
et al. [4], the prescription of CRT-D is currently restricted to
patients in need of secondary prevention of ventricular ar-
rhythmias or, for primary prevention, in younger patients
without major concomitant illnesses. The preferential choice
of CRT-P for the remainder of the ambulatory patients in
NYHA class III or IV is currently acceptable. Because of
insufficient data regarding the performance of CRT-P in pa-
tients presenting in NYHA functional class I or II, CRT-D is
currently the device of choice for this sub-population.
In the choice between CRT-D and CRT-P, the 2013 ESC
guidelines - endorsed by our national society, the NVVC-
clearly state: Owing to the potential incremental survival
benefit of CRT-D over CRT-P, the prevailing opinion among
the members of this Task Force is in favour of a superiority of
CRT-D in terms of total mortality and sudden death. However,
no strict recommendations can be made, and the Task Force
prefers to merely offer guidance regarding the selection of
patients for CRT-D or CRT-P, based on overall clinical con-
dition, device-related complications and cost.
Speaking of device-related complications and costs, these
are crucial issues to be considered as there are still 20–30 %
non-responders to CRT despite following the appropriate
guideline indication [5–7]. Therefore, new strategies and more
appropriate CRT approaches have to be implemented provid-
ing higher rates of success.
Recently, Vernooij et al. [8] fromMaastricht (theNetherlands)
proposed new strategies to improve the outcome of CRT. As the
implantation of CRT devices comes with substantial costs, in
particular CRT-D, the authors plead for a more strict and rigid
application of the guidelines, or even extension of the guidelines.
Outcomes from CRT can be improved by appropriate patient
selection, careful positioning of right and left ventricular pacing
electrodes, and optimal timing of electrode stimulation. LBBB
remains the predominant substrate for CRT, and patients with
this conduction abnormality yield the most benefit. However,
other features, such as QRS morphology, mechanical
dyssynchrony, myocardial scarring, and the aetiology of heart
failure, might also determine the benefit of CRT. No single left
ventricular pacing site suits all patients, but a late-activated site,
during either the intrinsic LBBB rhythm or right ventricular
pacing, should be selected. Positioning the lead inside a scarred
region substantially impairs outcomes. Optimisation of stimula-
tion intervals improves cardiac pump function in the short term,
but CRT procedures must become easier and more reliable,
perhaps with the use of electrocardiographic measures, to im-
prove long-term outcomes. For instance, Molenaar et al. [9]
showed that a 10 % increase in stroke volume can be achieved
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for optimisation of atrioventricular (AV) delay during exercise.
In that study, a considerable number of patients showed benefit
with lengthening of the AV delay during exercise.
In summary, sharper indications for CRT, and the perma-
nent consideration of choosing CRT-P or CRT-D, would be
cost-saving and might provide health benefits. This is in line
with the recent findings by Looi et al. [10] who showed that
CRT-D did not offer additional survival advantage over CRT-
P at longer-term follow-up, as the clinical benefit of a defi-
brillator attenuated with time. As mentioned before, further
work is therefore needed to define which subsets of patients
would benefit from CRT in combination with an ICD.
Lastly, there remains an urgent need for randomised clini-
cal trials in CRT subgroups such as in patients with right
bundle branch block, NYHA Class I, atrial fibrillation, and
in patients with specific conditions (pacing in children, con-
genital heart disease). When these studies have been complet-
ed, then we might speak of true CRT optimisation to better
serve patients with chronic heart failure.
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